These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20501992)

  • 1. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Parfrey PS
    Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
    [No Abstract]   [Full Text] [Related]  

  • 2. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Singh AK
    Am J Nephrol; 2010; 31(6):552-6; discussion 563-4. PubMed ID: 20501988
    [No Abstract]   [Full Text] [Related]  

  • 3. Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
    Locatelli F; Del Vecchio L
    Am J Nephrol; 2010; 31(6):557-60; discussion 561-2. PubMed ID: 20501989
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 5. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 6. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of anemia in chronic kidney disease: understandings in 2006.
    Levin A
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESAs in dialysis patients: are you a hedgehog or a fox?
    Singh AK
    J Am Soc Nephrol; 2010 Apr; 21(4):543-6. PubMed ID: 20357173
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anemia: guidelines comparison].
    Del Vecchio L
    G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The target hemoglobin in non-dialysis CKD: still a matter for debate?
    Kuriyama S
    Clin Exp Nephrol; 2010 Jun; 14(3):298-9. PubMed ID: 20300796
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality of life in CKD patients treated with erythropoiesis-stimulating agents.
    Parfrey PS; Wish T
    Am J Kidney Dis; 2010 Mar; 55(3):423-5. PubMed ID: 20189050
    [No Abstract]   [Full Text] [Related]  

  • 19. Do we know the correct hemoglobin target for anemic patients with chronic kidney disease?
    Foley RN
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):678-84. PubMed ID: 17699272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.